The Ball Aerospace & Technologies Corp. Ralph camera aboard the New Horizons mission will provide the closest images we have ever seen of Pluto when the spacecraft arrives at the dwarf planet on July 14.
Ralph, the main “eyes” of New Horizon is designed to help scientists map the surface geology of Pluto and its moons, and investigate Kuiper Belt objects. The small but powerful Ralph weighs only 23 pounds and operates on approximately seven watts, the power of a standard night light. The entire telescope operates around 220 K (-60°F) in the cold darkness of the outer solar system. After a journey of more than nine years, Ralph will capture the first ever close-up snapshots of Pluto when New Horizons passes within 7,000 miles of the tiny, icy dwarf planet.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7530151-ball-aerospace-new-horizons-mission-pluto/
Remote Control Cable Trackers Seen Above The Astronaut in The Nevada Fake Moon Bay.
ALL NASA FOOTAGE USED IN THIS VIDEO IS PUBLIC DOMAIN. THE USE OF ANY COPYRIGHTED MATERIAL IS USED UNDER THE GUIDELINES OF "FAIR USE" IN TITLE 17 § 107 OF THE UNITED STATES CODE. SUCH MATERIAL REMAINS THE COPYRIGHT OF THE ORIGINAL HOLDER AND IS USED HERE FOR THE PURPOSES OF EDUCATION, COMPARISON, AND CRITICISM ONLY. NO INFRINGEMENT OF COPYRIGHT IS INTENDED.
Astronaut Says Walt Disney Should Be Winding Us Down in LM Landing.
Video as You Hear it From NASA Public Domain Movie 'Apollo 11 For All Mankind'
ALL NASA FOOTAGE USED IN THIS VIDEO IS PUBLIC DOMAIN. THE USE OF ANY COPYRIGHTED MATERIAL IS USED UNDER THE GUIDELINES OF "FAIR USE" IN TITLE 17 § 107 OF THE UNITED STATES CODE. SUCH MATERIAL REMAINS THE COPYRIGHT OF THE ORIGINAL HOLDER AND IS USED HERE FOR THE PURPOSES OF EDUCATION, COMPARISON, AND CRITICISM ONLY. NO INFRINGEMENT OF COPYRIGHT IS INTENDED.
Lamp Lights Are Seen Over The Fake Model Moon.
ALL NASA FOOTAGE USED IN THIS VIDEO IS PUBLIC DOMAIN. THE USE OF ANY COPYRIGHTED MATERIAL IS USED UNDER THE GUIDELINES OF "FAIR USE" IN TITLE 17 § 107 OF THE UNITED STATES CODE. SUCH MATERIAL REMAINS THE COPYRIGHT OF THE ORIGINAL HOLDER AND IS USED HERE FOR THE PURPOSES OF EDUCATION, COMPARISON, AND CRITICISM ONLY. NO INFRINGEMENT OF COPYRIGHT IS INTENDED.
Turning Device Seen on Lunar Module Miniature Model.
ALL NASA FOOTAGE USED IN THIS VIDEO IS PUBLIC DOMAIN. THE USE OF ANY COPYRIGHTED MATERIAL IS USED UNDER THE GUIDELINES OF "FAIR USE" IN TITLE 17 § 107 OF THE UNITED STATES CODE. SUCH MATERIAL REMAINS THE COPYRIGHT OF THE ORIGINAL HOLDER AND IS USED HERE FOR THE PURPOSES OF EDUCATION, COMPARISON, AND CRITICISM ONLY. NO INFRINGEMENT OF COPYRIGHT IS INTENDED.
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
The Egyptian Ministry of Antiquities is pleased to announce the launch of an egyptian – international Project using non-invasive and non-destructive surveying techniques for the scanning of Egyptian Pyramids under the title “ScanPyramids” project.
Just because a mystery is 4500 years old doesn’t mean it can’t be solved…” This could be the motto of the exceptional scientific mission launched October 25, 2015, under the authority of the Egyptian Ministry of Antiquities, initiated, designed and coordinated by the Faculty of Engineering of Cairo and the French HIP.Institute (Heritage, Innovation and Preservation). Radiographic muons, aka cosmic particles, infrared thermography, photogrammetry, scanner and 3D reconstruction: the most innovative technologies will be used by researchers of international renown and three major universities: the Faculty of Engineering of Cairo University, Université Laval of Quebec and Nagoya University of Japan. Their goal: to probe the heart of the largest pyramids of Egypt, without drilling the slightest opening.
Four millennia after their construction, these ancient giants are far from having yielded their secrets. The first mystery concerns their construction, especially Khufu, the last of the Seven Wonders of the Ancient World still existing: it is still impossible to describe with certainty how this stone monument, the largest ever built by humans, was erected.
The “ScanPyramids” project has already been approved by the permanent committee of the Ministry of Antiquities and has obtained all necessary permissions from concerned authorities. With a base of more than 5 hectares, its original height of almost 150 meters and a mass of 5 million tons, how was it possible to construct such a wonder in only 25 years?
To view the multimedia release go to:
http://www.multivu.com/players/uk/7671551-scanpyramids-project-launch-egyptian/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Hennessy V.S, the world’s #1 Cognac, announces the launch of The Piccards, the fourth installment of the brand’s award-winning Wild Rabbit advertising campaign. The effort centers on the theme of pushing the limits of potential and is set to roll out across digital and broadcast platforms starting this month. The new creative continues to bring to life the spirit of Hennessy’s ‘Never stop. Never settle.’ mantra, this time through the remarkable true story of the Piccards, a pioneering family of explorers whose relentless pursuits pushed the limits of potential and made history.
Breaking barriers and records is what the Piccard family has been good at for generations: in 1931, Auguste Piccard became the first man to touch the edge of space – taking flight in a pressurized capsule and balloon to reach the stratosphere. Three decades later, his son Jacques went the other direction and modified his invention to become the first man to reach the furthest depths of the ocean.
To view the multimedia release go to:
http://www.multivu.com/players/English/7813051-hennessy-the-piccards-wild-rabbit/
Camp Invention, the nation’s premier summer enrichment program for over 25 years, has been providing children in grades one through six the opportunity to exercise their curiosity, amplify their creativity and be adaptive to different environments.
A program of the National Inventors Hall of Fame, developed in partnership with the United States Patent and Trademark Office, Camp Invention leverages hands-on activities to promote STEM learning and build 21st century skills. The program curriculum is created new every year and is inspired by some of our nation’s most brilliant minds. These innovation experts include Inductees of the National Inventors Hall of Fame as well as a team of experienced educators.
To view the multimedia release go to:
http://www.multivu.com/players/English/7667852-camp-invention-stem-epic-curriculum/
